A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: A subdivision of the original high-risk group on the basis of outcome
Hsuan-Ying Huang(Chang Gung University), David Lu(Chi Mei Medical Center), Chien‐Feng Li(National Sun Yat-sen University), Ching-Nan Lin(Chi Mei Medical Center), Wenwei Huang(National Cheng Kung University), Ching‐Yeh Hsiung(Chang Gung University), Yih‐Huei Uen(Chi Mei Medical Center), Tsung‐Hui Hu(National Sun Yat-sen University)
Cited by 106
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Hepatogastroenterology
|Hepatogastroenterology|2012|536
Pre-S Deletion and Complex Mutations of Hepatitis B Virus Related to Advanced Liver Disease in HBeAg-Negative Patients
|Gastroenterology|2007|232
Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|Liver International|2016|221
Clinical characteristics and prognostic factors of splenic abscess: A review of 67 cases in a single medical center of Taiwan
|World Journal of Gastroenterology|2006|217